MOH — authorised 4 June 1965
- Marketing authorisation holder: ADVANCE BIOFACTURES
- Status: likely_approved
MOH authorised Xiaflex on 4 June 1965
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 4 June 1965.
ADVANCE BIOFACTURES holds the Israeli marketing authorisation.